The benefits of semaglutide have far exceeded our initial imagination

Semaglutide has too many benefits, far beyond our imagination. 

It completely changes healthcare by slowing down the aging process, allowing people to live longer and healthier lives.

This study is from the Select trial in the United States, which studied 17604 overweight or obese people aged 45 years or older with cardiovascular disease but no diabetes. They received treatment with semaglutide or placebo and were followed up for over three years.

During the study period, a total of 833 participants died, of which 58% were related to cardiovascular causes and 42% were related to other causes, with infection being the most common cause of death in the latter. The study found that it is crucial that people taking semaglutide have a lower likelihood of dying from infection compared to the placebo group, and it also continues to reduce the risk of adverse cardiovascular consequences.

The significant decrease in non cardiovascular mortality, especially infection mortality, is surprising, "said Benjamin Scirica, a Harvard professor and lead author of one of the studies. These research findings further indicate that overweight and obesity increase the risk of death caused by multiple etiologies, which can be altered through therapies such as semaglutide.

The demand for GLP-1 such as semaglutide and tirzepatide is constantly increasing

With the increasing prevalence of obesity and type 2 diabetes, the demand for GLP-1 receptor agonists will increase significantly. According to the global statistics of the World Health Organization, the incidence rate of adult obesity has more than doubled since 1990. In 2014, 8.5% of adults over 18 years old had diabetes.

More worrisome is that the death rate of diabetes is also rising. Although the probability of death from other common non communicable diseases (including cancer, cardiovascular diseases and chronic respiratory diseases) between the ages of 30 and 70 has decreased by 22% between 2000 and 2019, WHO reports that the age standardized mortality rate of diabetes has increased by 3%. In low - and middle-income countries, this ratio increased by 13% in the same year.

There is an urgent need to optimize diabetes and weight management care, and GLP-1 receptor agonists may be part of the solution in some cases. By 2033, GlobalData predicts that these drugs will generate $168 billion in sales in 68 pharmaceutical markets, with North America accounting for 68%.